ClinicalTrials.gg
RecruitingNCT05035498Updated Feb 2, 2024

Prophylactic Norepinephrine and Phenylephrine Infusion for Hemodynamic Effects in Patients With Preeclampsia

An interventional study of Phenylephrine and Norepinephrine in Hemodynamic Instability, sponsored by General Hospital of Ningxia Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.

Planned enrollment
14th of 19
72 · median 180
Started
2024
with 4 others
No phase
12 of 36
5 open now
Primary completion
2025-04
later than 3 of 12 live
Registered
16th of 36
by date
Lead sponsor
4 of 36
General Hospital of Ningxia Medical University

Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 14th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 16th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pre-Eclampsia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the maternal cardiac output response to prophylactic norepinephrine and phenylephrine infusion for postspinal anesthesia hypotension in parturients with preeclampsia undergoing cesarean section.

Read the detailed description

Preeclampsia, which affects 5% to 7% of parturients, is a significant cause of maternal and neonatal morbidity and mortality. Because of constricted myometrial spiral arteries with exaggerated vasomotor responsiveness, though blood pressure in parturients with preeclampsia are apparently higher than healthy parturients, placental hypoperfusion is more common. Spinal anesthesia is still the preferred mode of anesthesia in parturients with preeclampsia for cesarean section. In preeclampsia parturients, spinal anesthesia improve intervillous blood flow (provided that hypotension is avoided) which contribute to increase placental perfusion. Even so, 17-26% parturients with preeclampsia experienced postspinal anesthesia hypotension due to the extensive sympathetic block that occurred with spinal anesthesia. As a potential substitute drug for phenylephrine and ephedrine, norepinephrine has gained traction for use in parturients undergoing cesarean section. However, hemodynamic effects of the prophylactic norepinephrine infusion is still unknown. The purpose of this study is to investigate the maternal cardiac output response to prophylactic norepinephrine and phenylephrine infusion for postspinal anesthesia hypotension in parturients with preeclampsia undergoing cesarean section.

03

Conditions studied

  • Hemodynamic Instability

Browse trials for

Keywords

  • Norepinephrine
  • Phenylephrine
  • Hemodynamic effects
  • Preeclampsia
  • Cesarean section
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-45 years
  • Primipara or multipara
  • Singleton pregnancy ≥32 weeks
  • physical status classification II to III
  • Scheduled for cesarean section under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Baseline blood pressure ≥180 mmHg
  • Body height \< 150 cm
  • Body weight > 100 kg or (BMI) ≥ 40 kg/m2
  • Eclampsia or chronic hypertension
  • \< 7g/dl
  • Fetal distress, or known fetal developmental anomaly
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    Phenylephrine group

    Phenylephrine infusion simultaneous with spinal anesthesia

    Drug: Phenylephrine

  • Experimental
    Norepinephrine group

    Norepinephrine infusion simultaneous with spinal anesthesia

    Drug: Norepinephrine

Interventions

  • A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block

    Also known as: Vasopressors

  • A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block

    Also known as: Vasopressors

06

What researchers measure

Primary outcomes

  1. Cardiac output (CO)

    Evaluated by the VIGILCO monitoring system

    Time frame: 1-30 minutes after spinal anesthesia

  2. Stroke volume (SV)

    Evaluated by the VIGILCO monitoring system

    Time frame: 1-30 minutes after spinal anesthesia

  3. Systemic vascular resistance (SVR)

    Evaluated by the VIGILCO monitoring system

    Time frame: 1-30 minutes after spinal anesthesia

Secondary outcomes

  1. Overall stability of systolic blood pressure control versus baseline

    Evaluated by performance error (PE)

    Time frame: 1-30 minutes after spinal anesthesia

  2. Overall stability of heart rate control versus baseline

    Evaluated by performance error (PE)

    Time frame: 1-30 minutes after spinal anesthesia

  3. The incidence of post-spinal anesthesia hypotension

    Systolic blood pressure (SBP) \< 80% of the baseline

    Time frame: 1-30 minutes after spinal anesthesia.

  4. The incidence of severe post-spinal anesthesia hypotension.

    Systolic blood pressure (SBP) \< 60% of the baseline

    Time frame: 1-30 minutes after spinal anesthesia.

  5. The incidence of hypertension.

    Systolic blood pressure (SBP) \>120% of the baseline.

    Time frame: 1-30 minutes after spinal anesthesia

  6. The incidence of bradycardia.

    Heart rate \< 60 beats/min.

    Time frame: 1-30 minutes after spinal anesthesia

  7. The incidence of nausea and vomiting.

    Presence of nausea and vomiting in patients after spinal anesthesia

    Time frame: 1-30 minutes after spinal anesthesia

  8. pH

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery

  9. Partial pressure of oxygen (PO2)

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery

  10. Base excess (BE)

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery

  11. APGAR score

    A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

    Time frame: 1 min after delivery

  12. APGAR score

    A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

    Time frame: 5 min after delivery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Apr 2025, 14 months after the start.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 14 months is below that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2021
First posted
Sep 5, 2021
StartActual
Feb 1, 2024
Primary completionEst.
Apr 21, 2025
CompletionEst.
Apr 21, 2025
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05035498
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Feb 1, 2024
Primary completion
Apr 21, 2025 (estimated)
Completion
Apr 21, 2025 (estimated)
Last update
Feb 2, 2024

Study contacts

Xinli Ni, Dr.
Contact
xinlini6@nyfy.com.cn
86-951-674-3252
Yi Chen, M.D.
Contact
czzyxgp@163.com
86-951-674-3252
Xinli Ni, Dr.
study chair · General Hospital of Ningxia Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Norepinephrine

Start the discussion